ARS Pharmaceuticals Inc (SPRY) concluded trading on Thursday at a closing price of $14.31, with 8.86 million shares of worth about $126.81 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 9.66% during that period and on March 20, 2025 the price saw a gain of about 22.83%. Currently the company’s common shares owned by public are about 97.15M shares, out of which, 51.30M shares are available for trading.
Stock saw a price change of 19.75% in past 5 days and over the past one month there was a price change of 19.25%. Year-to-date (YTD), SPRY shares are showing a performance of 35.64% which increased to 56.91% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $7.55 but also hit the highest price of $18.51 during that period. The average intraday trading volume for ARS Pharmaceuticals Inc shares is 1.34 million. The stock is currently trading 27.68% above its 20-day simple moving average (SMA20), while that difference is up 19.21% for SMA50 and it goes to 16.67% higher than SMA200.
ARS Pharmaceuticals Inc (NASDAQ: SPRY) currently have 97.15M outstanding shares and institutions hold larger chunk of about 51.01% of that.
The stock has a current market capitalization of $1.39B and its 3Y-monthly beta is at 0.94. It has posted earnings per share of -$0.51 in the same period. It has Quick Ratio of 12.50 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SPRY, volatility over the week remained 8.59% while standing at 7.02% over the month.
Stock’s fiscal year EPS is expected to drop by -1070.83% while it is estimated to increase by 68.45% in next year. EPS is likely to grow at an annualized rate of 75.98% for next 5-years, compared to annual growth of -1.44% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Scotiabank on March 07, 2025 offering a Sector outperform rating for the stock and assigned a target price of $30 to it. Coverage by Oppenheimer stated ARS Pharmaceuticals Inc (SPRY) stock as an Outperform in their note to investors on February 10, 2025, suggesting a price target of $40 for the stock. On August 20, 2024, Cantor Fitzgerald Initiated their recommendations, while on August 13, 2024, Raymond James Upgrade their ratings for the stock with a price target of $22. Stock get an Outperform rating from Leerink Partners on August 12, 2024.
